Literature DB >> 1890836

In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin.

K A Zirvi1, U Atabek.   

Abstract

We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549). DFMO showed a dose-dependent growth-inhibitory effect against human colon tumor xenograft and lung adenocarcinoma cells. Growth-inhibitory activity of DFMO against T6 cells was reversed completely when the cells were treated simultaneously with putrescine (PU) (10(-6) M) and DFMO (10(-3) M). When 5-FU and DFMO were used in combination against T6 cells, no antagonism or synergism between the two drugs was seen. However, in the case of A549 cells, when DFMO was used in combination with DX, there was a consistent increase in growth inhibition that surpassed the inhibition of either agent given alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890836     DOI: 10.1002/jso.2930480107

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites.

Authors:  María Virtudes Céspedes; Carolina Espina; Miguel Angel García-Cabezas; Manuel Trias; Alicia Boluda; María Teresa Gómez del Pulgar; Francesc Josep Sancho; Manuel Nistal; Juan Carlos Lacal; Ramon Mangues
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

2.  The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Authors:  Allison Pledgie-Tracy; Madhavi Billam; Amy Hacker; Michele D Sobolewski; Patrick M Woster; Zhe Zhang; Robert A Casero; Nancy E Davidson
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-30       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.